Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.6.2351

Effects of Metformin on Cell Kinetic Parameters of MCF-7 Breast Cancer Cells in Vitro  

Topcul, Mehmet (Department of Biology, Faculty of Science, Istanbul University)
Cetin, Idil (Department of Biology, Faculty of Science, Istanbul University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.6, 2015 , pp. 2351-2354 More about this Journal
Abstract
In this study, the antiproliferative effects of the metformin was evaluated on MCF-7 Cells (human breast adenocarcinoma cell line). For this purpose cell kinetic parameters including cell proliferation assay, mitotic index and labelling index analysis were used. $30{\mu}M$, $65{\mu}M$ and $130{\mu}M$ Metformin doses were applied to cells for 24, 48 and 72 hours. The results showed that there was a significant decrease in cell proliferation, mitotic index and labelling index for all experimental groups (p<0.05) for all applications.
Keywords
Breast cancer; MCF-7 cells; cell proliferation; mitotic index labelling index;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Bao B, Wang Z, Ali S, et al (2012). Metformin inhibits cell proliferation, migration and invasion by attenuating csc function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res, 5, 355-64.   DOI
2 Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006). Increased cancerrelated mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29, 254-8.   DOI
3 Cairns RA, Harris IS, Mak TW (2011). Regulation of cancer cell metabolism. Nat Rev Cancer, 11, 85-95.   DOI   ScienceOn
4 Calle EE, Kaaks R (2004). Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 4, 579-91.   DOI
5 Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009). Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev, 18, 701-5.   DOI
6 Cetin I, Topcul M (2012). Cancer stem cells in oncology. J BUON, 17, 644-8.
7 Cetin I, Topcul M (2014). Triple negative breast cancer. Asian Pac J Cancer Prev, 15, 2427- 31.   DOI
8 Costa D, Gigoni A, Wurth R, et al (2014). Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. Cancer Cell International, 14, 59.   DOI
9 Cusi K, Consoli A, DeFronzo RA (1996). Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 81, 4059-67.
10 DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab, 7, 11-20.   DOI
11 Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res, 67, 10804-12.   DOI
12 Dowling RJO, Goodwin PJ, Stambolic V (2011). Understanding the benefit of metformin use in cancer treatment. BMC Medicine, 9, 33.   DOI
13 Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5.   DOI
14 Goodwin PJ, Stambolic V, Lemieux J, et al (2011). Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat, 126, 215-20.   DOI
15 Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11.   DOI
16 Koppenol WH, Bounds PL, Dang CV (2011). Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 11, 325-37.   DOI   ScienceOn
17 Renehan AG, Frystyk J, Flyvbjerg A (2006). Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab, 17, 328-36.   DOI
18 Kourelis TV, Siegel RD (2012). Metformin and cancer: new applications for an old drug. Med Oncol, 29, 1314-27.   DOI
19 Larsson SC, Mantzoros CS, Wolk A (2007). Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer, 121, 856 -62.   DOI
20 Pollak MN, Schernhammer ES, Hankinson SE (2004). Insulin-like growth factors and neoplasia. Nat Rev Cancer, 4, 505-18.   DOI
21 Sun XJ, Zhang P, Li HH, Jiang ZW, et al (2014). Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating e-cadherin and mmp-9. Asian Pac J Cancer Prev, 15, 4019-23.   DOI
22 Tabrizi AD, Melli MS, Foroughi M, Ghojazadeh M, Bidadi S (2014). Antiproliferative effect of metformin on the endometrium - a clinical trial. Asian Pac J Cancer Prev, 15, 10067-70.
23 Topcul M, Topcul F, Cetin I (2013). Effects of femara and tamoxifen on proliferation of FM3A cells in culture. Asian Pac J Cancer Prev, 14, 2819-22.   DOI   ScienceOn
24 Vander Heiden MG (2011). Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov, 10, 671-84.   DOI   ScienceOn
25 Vander Heiden MG, Cantley LC, Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-33.   DOI   ScienceOn
26 Ward PS, Thompson CB (2012). Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell, 21, 297-308.   DOI   ScienceOn
27 Yee D (2006). Targeting insulin-like growth factor pathways. Br J Cancer, 94, 465-8.   DOI
28 Witters LA (2001). The blooming of the French lilac. J Clin Invest, 108, 1105-7.   DOI   ScienceOn
29 Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005). Diabetes mellitus and breast cancer. Lancet Oncol, 6, 103-11.   DOI
30 Xiong Y, Lu QJ, Zhao J, Wu GY (2012). Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev, 13, 3275-79.   DOI